申请人:Dana-Farber Cancer Institute, Inc.
公开号:US10000483B2
公开(公告)日:2018-06-19
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.
本发明提供了新颖的式(I)化合物及其药学上可接受的盐、溶液剂、水合物、多晶型、共晶体、同系物、立体异构体、同位素标记的衍生物、原药及其组合物。还提供了涉及式(I)或(II)化合物或其组合物的方法和试剂盒,用于治疗或预防受试者的多种疾病(如增殖性疾病(如癌症、良性肿瘤、血管生成、炎症性疾病、自身免疫性疾病)和代谢性疾病(如糖尿病(如 2 型糖尿病、妊娠糖尿病))。使用式(I)或(II)化合物或其组合物治疗患有疾病的受试者,可下调激酶(如酪氨酸激酶,如Tec激酶,特别是X染色体上的骨髓激酶(BMX))的表达和/或抑制其活性,从而抑制受试者体内的酪氨酸激酶单体。